These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 22477711)
21. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026 [TBL] [Abstract][Full Text] [Related]
22. PHA665752 inhibits the HGF-stimulated migration and invasion of cells by blocking PI3K/AKT pathway in uveal melanoma. Wang Z; He C; Liu L; Ma N; Chen X; Zheng D; Qiu GH Neoplasma; 2017; 64(3):377-388. PubMed ID: 28253717 [TBL] [Abstract][Full Text] [Related]
23. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. Li J; Liu X; Li C; Wang W J Cell Biochem; 2019 Aug; 120(8):12412-12421. PubMed ID: 30825222 [TBL] [Abstract][Full Text] [Related]
24. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ J Biol Chem; 2021; 296():100403. PubMed ID: 33577798 [TBL] [Abstract][Full Text] [Related]
25. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells. Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235 [TBL] [Abstract][Full Text] [Related]
26. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells. Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401 [TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215 [TBL] [Abstract][Full Text] [Related]
28. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways. Xie X; Xie S; Xie C; Fang Y; Li Z; Wang R; Jiang W J Cell Mol Med; 2019 Nov; 23(11):7545-7553. PubMed ID: 31508890 [TBL] [Abstract][Full Text] [Related]
29. Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway. Farhan M; Silva M; Xingan X; Zhou Z; Zheng W Oxid Med Cell Longev; 2021; 2021():9911537. PubMed ID: 34931134 [TBL] [Abstract][Full Text] [Related]
30. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486 [TBL] [Abstract][Full Text] [Related]
32. The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells. Zheng L; Pan J Curr Cancer Drug Targets; 2018; 18(10):988-998. PubMed ID: 29692251 [TBL] [Abstract][Full Text] [Related]
33. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation. Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684 [TBL] [Abstract][Full Text] [Related]
34. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748 [TBL] [Abstract][Full Text] [Related]
36. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. Némati F; de Montrion C; Lang G; Kraus-Berthier L; Carita G; Sastre-Garau X; Berniard A; Vallerand D; Geneste O; de Plater L; Pierré A; Lockhart B; Desjardins L; Piperno-Neumann S; Depil S; Decaudin D PLoS One; 2014; 9(1):e80836. PubMed ID: 24454684 [TBL] [Abstract][Full Text] [Related]
37. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035 [TBL] [Abstract][Full Text] [Related]
38. Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. van Ginkel PR; Darjatmoko SR; Sareen D; Subramanian L; Bhattacharya S; Lindstrom MJ; Albert DM; Polans AS Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1299-306. PubMed ID: 18385041 [TBL] [Abstract][Full Text] [Related]
39. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma Zhou J; Jin B; Jin Y; Liu Y; Pan J Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629 [TBL] [Abstract][Full Text] [Related]
40. Verification of EZH2 as a druggable target in metastatic uveal melanoma. Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]